Curbstone Financial Management Corp decreased its holdings in shares of Smith & Nephew plc (NYSE:SNN – Free Report) by 21.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,650 shares of the medical equipment provider’s stock after selling 3,800 shares during the quarter. Curbstone Financial Management Corp’s holdings in Smith & Nephew were worth $425,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in SNN. Parallel Advisors LLC boosted its holdings in Smith & Nephew by 150.9% in the fourth quarter. Parallel Advisors LLC now owns 1,533 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 922 shares during the last quarter. Clear Street Markets LLC boosted its holdings in Smith & Nephew by 120.9% in the fourth quarter. Clear Street Markets LLC now owns 175,006 shares of the medical equipment provider’s stock valued at $4,774,000 after acquiring an additional 95,765 shares during the last quarter. Syon Capital LLC acquired a new position in Smith & Nephew in the fourth quarter valued at $356,000. Goldman Sachs Group Inc. boosted its holdings in Smith & Nephew by 3.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,343,712 shares of the medical equipment provider’s stock valued at $36,656,000 after acquiring an additional 44,445 shares during the last quarter. Finally, Nomura Holdings Inc. acquired a new position in Smith & Nephew in the fourth quarter valued at $887,000. Institutional investors and hedge funds own 25.64% of the company’s stock.
Smith & Nephew Stock Up 0.5 %
NYSE:SNN traded up $0.16 during mid-day trading on Friday, hitting $29.99. The company had a trading volume of 382,559 shares, compared to its average volume of 866,551. The business has a fifty day simple moving average of $30.54 and a 200-day simple moving average of $27.31. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. Smith & Nephew plc has a 1 year low of $21.52 and a 1 year high of $31.72.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Smith & Nephew
Smith & Nephew Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
See Also
- Five stocks we like better than Smith & Nephew
- The Most Important Warren Buffett Stock for Investors: His Own
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- 10 Best Airline Stocks to Buy
- MarketBeat Week in Review – 9/30 – 10/4
- Investing In Preferred Stock vs. Common Stock
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.